The Golden Ticket

ONO PHARMA USA Announces 2024 Golden Ticket Competition Now Accepting Applications from Innovative Startups

Retrieved on: 
Thursday, May 2, 2024
Immunology, Golden Ticket, ONO, Patient, Neurology, MBC, Kendall Square, The Golden Ticket, LabCentral, Organization

CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company. The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.

Key Points: 
  • CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company.
  • The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.
  • The Golden Ticket awards provide two promising early-stage R&D companies lab space and mentorship, components that are vital to the success of promising life science businesses.
  • The competition seeks proposals from startup companies in the oncology, immunology, neurology, and specialty areas.

UTR Sports Announces Franklin Sports as Official Ball of Pickleball Amateur Series

Retrieved on: 
Thursday, February 22, 2024
X-40, USA Pickleball, The Golden Ticket, UTR, Golden Ticket, Pickleball, Growth, Sport, CO, Partnership, Hunting

Palo Alto, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- UTR Sports (formerly Universal Tennis) is announcing Franklin Sports , a leading manufacturer and retailer in the sporting goods industry, as the official pickleball ball partner of UTR Sports and the UTR Sports Pickleball Amateur Series .

Key Points: 
  • Palo Alto, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- UTR Sports (formerly Universal Tennis) is announcing Franklin Sports , a leading manufacturer and retailer in the sporting goods industry, as the official pickleball ball partner of UTR Sports and the UTR Sports Pickleball Amateur Series .
  • The UTR Sports Pickleball Amateur Series is a new year-round series of pickleball tournaments held across the United States throughout 2024.
  • Two of the Pickleball Amateur Series events are USA Pickleball Golden Ticket qualifiers, where players have a chance to earn the exclusive opportunity to pre-register for the 2024 USA Pickleball National Championships.
  • "Franklin Sports is thrilled to become the official ball partner of UTR Sports,” said Adam Franklin, President of Franklin Sports.

Dollywood’s Big Bear Mountain Now Open, Sending Riders to Search for “Big Bear”

Retrieved on: 
Friday, May 12, 2023
Other Travel, Lodging, Destinations, Travel, Vacation, Family, Consumer, Tourist Attractions, Covenant Health, Herschend Family Entertainment, Applause Award, Great Smoky Mountains, Amusement Today, Pigeon Forge, Tennessee, The Golden Ticket, Multimedia, Great Smoky Mountains National Park, Big Bear, Element, Beauty, Brass, SUV, Water, Golden Ticket, Wilderness, USA Today, Amusement park, Nightclub, Big Bear Mountain, Vekoma, Tripadvisor, Humana, Smokies, Dollywood

View the full release here: https://www.businesswire.com/news/home/20230512005051/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230512005051/en/
    Dollywood's Big Bear Mountain, the theme park's longest roller coaster, officially opened on Friday, May 12.
  • Dollywood guests are invited to assist Wildwood Grove’s resident wilderness explorer, Ned Oakley, in his quest to find Big Bear.
  • In addition to the opening of Big Bear Mountain, Dollywood’s HeartSong Lodge & Resort is slated to open this November.
  • For more information about Big Bear Mountain, Dollywood’s HeartSong Lodge & Resort, and the 2023 operating season, please visit dollywood.com .

Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation

Retrieved on: 
Tuesday, April 25, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Acceleration, Joint capsule, GALA, Amaravati seed capital road, IMCB, Agency for Science, Technology and Research, Arthritis, Institute of Molecular and Cell Biology, Neoplasm, SEEDS, Connective tissue, Biologic, The Golden Ticket, Toxicity, Antibody, Albatroz-class patrol boat, Duke–NUS Medical School, Cell biology, Patient, Extracellular matrix, Golden Ticket, CSCB, Growth, Therapy, Recurrence, Glycosylation, Metastasis, Pharmaceutical industry, Vaccine, Amgen, Cancer

The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.

Key Points: 
  • The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.
  • Cancer that has metastasized, spreading to other parts of the body, is notoriously difficult to treat and accounts for most cancer deaths.
  • Albatroz has secured exclusive rights on a highly specific and novel target that blocks tumor growth and recurrence, including a range of therapeutic antibodies that inhibit this target.
  • Activation of the target occurs specifically in tumors and arthritic synovial membranes, connective tissue that lines the joint capsule.

ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs

Retrieved on: 
Tuesday, April 18, 2023
Golden Ticket, ONO, Organization, MBC, LabCentral, The Golden Ticket, Neurology, Pharmaceutical industry, Film industry

CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco, to award each organization one Golden Ticket for an innovative life sciences startup company.

Key Points: 
  • CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco, to award each organization one Golden Ticket for an innovative life sciences startup company.
  • The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (ONO), and applications will be received through May 2023.
  • The Golden Ticket awards provide promising early-stage R&D companies lab space and mentorship, two components vital to the success of nascent life science businesses.
  • "As longtime believers in open innovation and the power of partnerships, we are excited once again to offer this Golden Ticket competition in collaboration with LabCentral and MBC BioLabs," said Kunihiko Ito, President and CEO of ONO PHARMA USA.

Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

Retrieved on: 
Wednesday, March 1, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pillar, Boehringer Ingelheim, Therapy, Alnylam Pharmaceuticals, DSM-IV codes, Immune system, Disease, Ageing, Drug development, Patient, Biology, Kendall Square, Machine learning, General partnership, HOPE, The Golden Ticket, George Church, Novo Nordisk, Vaccine, Thymus, Pharmaceutical industry, Pfizer

The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.

Key Points: 
  • The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.
  • The funding will also be used to develop its thymic cell engineering platform and expand into additional indications across areas of unmet clinical need in immunology.
  • The thymus is a critical organ in the immune system that regulates and develops T cells, which are essential for fighting infection and disease, along with mounting effective responses to vaccines.
  • Thymmune has also received funding via Wellcome Leap’s inaugural HOPE program, along with an NIH/NIAID Fast-Track SBIR.

BOLDEN THERAPEUTICS RECEIVES $406,466 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS

Retrieved on: 
Friday, September 16, 2022
Adult, ASO, National, Peripheral nervous system, Therapy, The Golden Ticket, Ageing, LabCentral, Brain, Entrepreneurship, Research, Principal, Stem cell, National Institute on Aging, NIA, CEO, SBIR, Neurogenesis, CNS, Heart, Biotechnology, Kendall Square, Neuron, Ticket, Alzheimer's disease, National Institute, Pharmaceutical industry, Biogen

"This REDI award will provide important support to advance our antisense oligonucleotide program and further establish proof of concept in Alzheimer's disease models," said Johnny Page, Co-Founder and CEO of Bolden Therapeutics.

Key Points: 
  • "This REDI award will provide important support to advance our antisense oligonucleotide program and further establish proof of concept in Alzheimer's disease models," said Johnny Page, Co-Founder and CEO of Bolden Therapeutics.
  • The REDI grant mechanism provides bio-entrepreneurship training to facilitate more diverse career options for early-career scientists working in the fields of aging and aging-related diseases, such as Alzheimer's disease.
  • "I am very excited about this opportunity to advance my entrepreneurial skills," said Anne Valat, Ph.D., Principal Scientist of Bolden Therapeutics and Principal Investigator of the REDI SBIR grant.
  • The SBIR award is entitled 'Entrepreneurial development award for a novel Alzheimer's disease therapeutic' and will support further investigation of antisense candidates in vivo.

BOLDEN THERAPEUTICS RECEIVES $497,500 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS

Retrieved on: 
Wednesday, June 29, 2022
ASO, LabCentral, National, Heart, Peripheral nervous system, Biotechnology, SBIR, CEO, Adult, National Institute, Brain, National Institute on Aging, The Golden Ticket, CNS, Kendall Square, Ticket, Neurogenesis, Small Business Innovation Research, Therapy, NIA, Principal, Neuron, Entrepreneurship, Stem cell, Alzheimer's disease, Pharmaceutical industry, Biogen

CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.

Key Points: 
  • CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.
  • "This SBIR award from the NIA will further our development of our exon-skipping antisense oligonucleotide (ASO) candidates to modulate the expression of a genetically-validated target for increasing neurogenesis," said Johnny Page, Co-Founder and CEO of Bolden Therapeutics.
  • "With the support of these funds, we will be able to advance our ASO candidates in mouse models of Alzheimer's disease," said Anne Valat, Ph.D., Principal Scientist of Bolden Therapeutics and Principal Investigator of the SBIR grant.
  • The company is developing antisense oligonucleotides to modulate this genetically-validated target.

LG Chem Life Sciences Innovation Center and LabCentral Announce the 2022 Golden Ticket Winner – Rubik Therapeutics

Retrieved on: 
Wednesday, May 25, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Diabetes, Center for Cell and Gene Therapy, Kendall Square, Multimedia, LG Chem, Therapy, Lists of diseases, The Golden Ticket, Golden Ticket, Gene, NK, Safety, Heart, Cell, CAR, Inborn errors of metabolism, LabCentral, CEO, Pharmaceutical industry

Today, LG Chem Life Sciences Innovation Center announced that it has selected Rubik Therapeutics as the winner of their 2022 LabCentral Golden Ticket Program.

Key Points: 
  • Today, LG Chem Life Sciences Innovation Center announced that it has selected Rubik Therapeutics as the winner of their 2022 LabCentral Golden Ticket Program.
  • View the full release here: https://www.businesswire.com/news/home/20220525005287/en/
    LG Chem Life Sciences Innovation Center presents 2022 LabCentral Golden Ticket to Rubik Therapeutics.
  • (Photo: Business Wire)
    As a LabCentral sponsor, LG Chem Life Sciences Innovation Center can select a qualifying startup company each year to take up residence in LabCentrals Kendall Square facility through use of the Golden Ticket.
  • This year is the third year of LG Chem Life Sciences Innovation Centers Golden Ticket Program and it is designed to assist high-potential and innovative early-stage life science and biotech companies.

Bakar Labs and the Cystic Fibrosis Foundation Support Entrepreneurs to Develop New Genetic Therapies for CF

Retrieved on: 
Monday, April 18, 2022
Valencia CF Foundation, CF, University of California, Berkeley, Clinical trial, Cystic fibrosis, Cystic Fibrosis Foundation, Cell biology, BBH, Student, UC Berkeley College of Engineering, QB3, Bachelor of Engineering, Doctor of Philosophy, Bakar, Engineering, Translation, Gene editing, Entrepreneurship, Technology, Solution, UC, OBE, The Golden Ticket, Partnership, University, Health, Therapy, Berkeley, Management, Environmental remediation

Up to three potential winners will be provided lab space and facilities at Bakar Labs.

Key Points: 
  • Up to three potential winners will be provided lab space and facilities at Bakar Labs.
  • "Our double bottom line at Bakar Labs emphasizes public good on an equal basis with the potential for profit."
  • "Collaborating with the CF Foundation creates an extraordinary opportunity," said Gino Segr, PhD, managing director of Bakar Labs.
  • The CF Foundation has achieved global admiration for its support of disease-related research efforts, not only by scientists in academic labs but by entrepreneurs in startup companies.